Desmopressin for Antiplatelet-Associated Intracranial Hemorrhage: A Concise Review

Area of Science:

• Neuroscience
• Pharmacology
• Emergency Medicine

Background:

• Intracranial hemorrhage (ICH) presents significant risks, particularly when associated with antiplatelet medication use.
• Reversing antiplatelet effects is crucial for managing ICH and preventing further bleeding.

Purpose of the Study:

• To review the existing literature on the efficacy and safety of desmopressin for reversing antiplatelet therapy in patients with ICH.
• To synthesize current evidence to inform clinical practice and guideline development.

Main Methods:

• A comprehensive literature search was conducted using PubMed.
• Studies specifically investigating desmopressin for antiplatelet reversal in ICH were selected and reviewed.
• Data extraction included study population, design, methods, results, and clinical implications.

Main Results:

• Evidence regarding desmopressin's effectiveness in antiplatelet-associated ICH is mixed but suggests potential benefit.
• The risks associated with a single dose of desmopressin appear minimal compared to its potential advantages.
• Platelet transfusions are generally recommended only for patients undergoing neurosurgery until more robust evidence emerges.
• Guidelines suggest a weight-based desmopressin dosage of 0.4 mcg/kg administered over 30 minutes.

Conclusions:

• Current evidence supports the use of desmopressin as a potentially beneficial agent with low risk in managing antiplatelet-associated ICH.
• Desmopressin represents a viable option for reversing antiplatelet effects in this critical patient population.